Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood: Design of the EINSTEIN-Jr phase III study

Anthonie W. A. Lensing*, Christoph Male, Guy Young, Dagmar Kubitza, Gili Kenet, M. Patricia Massicotte, Anthony Chan, Angelo C. Molinari, Ulrike Nowak-Goettl, Akos F. Pap, Ivet Adalbo, William T. Smith, Amy Mason, Kirstin Thelen, Scott D. Berkowitz, Mark Crowther, Stephan Schmidt, Victoria Price, Martin H. Prins, Paul Monagle

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number34
Number of pages11
JournalThrombosis Journal
Volume16
DOIs
Publication statusPublished - 21 Dec 2018

Keywords

  • Anticoagulation
  • Bodyweight-adjusted dosing
  • Pediatric patients
  • Rivaroxaban
  • Venous thromboembolism
  • REPORTED TREATMENT SATISFACTION
  • ORAL RIVAROXABAN
  • ANTITHROMBOTIC THERAPY
  • THROMBOSIS
  • CHILDREN
  • POPULATION
  • DISEASE
  • RISK
  • DEFINITION
  • PREVENTION

Cite this

Lensing, A. W. A., Male, C., Young, G., Kubitza, D., Kenet, G., Massicotte, M. P., Chan, A., Molinari, A. C., Nowak-Goettl, U., Pap, A. F., Adalbo, I., Smith, W. T., Mason, A., Thelen, K., Berkowitz, S. D., Crowther, M., Schmidt, S., Price, V., Prins, M. H., & Monagle, P. (2018). Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood: Design of the EINSTEIN-Jr phase III study. Thrombosis Journal, 16, [34]. https://doi.org/10.1186/s12959-018-0188-y